Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Vectus Biosystems Ltd

VBS.AX ✓ COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.05

▲ +0.00%

Market Cap $3.23M · Vol 15.00K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

2.86

FWD: N/A

Market Cap

$3.23M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

0.00

Momentum

Beta

1.04

vs Market

52W High

$0.32

82.28% below

52W Low

$0.05

0.00% above

Volume

15.00K

Avg 33.20K

P/B

3.33

Price-to-book

ROE

N/A

Return on equity

Free Float

49.10%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Vectus Biosystems Ltd (VBS.AX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does VBS.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-5.06%

-31.82%

-53.13%

-40.00%

YTD

-58.33%

-54.55%

-72.91%

-95.45%

Financials & Valuation

TTM · Annual

Total Revenue	$5.14K
Net Income	$1.08M
Revenue Growth (YoY)	-9.77%
Gross Margin	100.00%
Operating Margin	-18,312.31%
Net Profit Margin	20,972.16%
ROE	N/A
ROA · ROIC	67.76% · 114.02%

P/E Ratio	2.86
Forward P/E (FY1)	N/A
PEG Ratio	0.02
P/S	931.31
P/B	3.33
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	62.18M

Technical Indicators

50-Day SMA	$0.08
200-Day SMA	$0.09
RSI (14)	0.00
Beta	1.04
52-Week High	$0.32
52-Week Low	$0.05

Volume Today	15.00K
Avg Daily Volume (30D)	33.20K
Relative Volume	0.45x
Volatility (10D)	57.89
Volatility (30D)	65.93
Free Float	49.10%

Analyst Consensus

N/A

Current Price $0.05

Mean Target N/A

52W Low$0.05 52W High$0.32

Current

Target

$0.05 $0.32

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG00BJMG5G0

ISINAU000000VBS9

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG +1.63% ONC BeOne Medicines AG +2.51% 068270.KS Celltrion, Inc. +7.50% MEDP Medpace Holdings, Inc. -3.32% ICLR ICON PLC -0.72%

Company Profile

Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.